{"entity":{"id":"nct04475523","kind":"trial","name":"Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies","aka":[],"tldr":"A phase 1 trial of CI-8993 run by Curis, Inc., completed.","summary":"Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies is a phase 1 interventional study registered as NCT04475523 by Curis, Inc., with 26 participants enrolled, started 2020-09-22. Conditions recorded: Solid Tumor. Interventions recorded: CI-8993.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04475523","url":"https://clinicaltrials.gov/study/NCT04475523"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ci-8993"],"companies":["immunext","curis","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04475523","phase":"1","setting":"Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies","sponsor":"Curis, Inc.","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04475523/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ci-8993","kind":"drug","name":"CI-8993","route":"/drugs/ci-8993/"}],"company":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/"},{"id":"immunext","kind":"company","name":"ImmuNext","route":"/companies/immunext/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}